Insider · CIK 0002108080
Laurence Matthew Skelton
Files at VERA (Vera Therapeutics, Inc.). First filing Feb 25, 2026, latest Feb 25, 2026.
Laurence Matthew Skelton files SEC Form 4 as officer at VERA (Vera Therapeutics, Inc.). Since Feb 25, 2026, Laurence Matthew Skelton has reported 0 open-market buys worth $0 and 1 open-market sell worth $66k, the latest filed on Feb 25, 2026.
A track record needs three past buys with six months of prices behind them; Laurence Matthew Skelton has 0, so none is measured yet.
The newest scored trade: sold $66k of VERA on Feb 23, 2026, filed Feb 25, 2026, scored 38 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $66k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VERA: Vera Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Vera Therapeutics, Inc. | $66k 1,582 shares | -2% | +123% from low-24% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 23, 2026 | VERA VERA THERAPEUTICS, INC. | 1,800 0.00% of outstanding | $76k | Feb 23, 2026 | none |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | VERA Vera Therapeutics, Inc. | SOpen-market sale Class A Common Stock | -1,582 | $41.98 | $66k | 64,218 | Feb 25, 2026 |
| Feb 4, 2026 | VERA Vera Therapeutics, Inc. | AGrant or award Class A Common Stock | +20,000 | $0.00 | $0 | 65,800 | Feb 6, 2026 |
| Feb 4, 2026 | VERA Vera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 6, 2026 |
Questions about Laurence Matthew Skelton
Answered from the filings on this page, as of the latest one.
Is Laurence Matthew Skelton buying or selling?
In the last 12 months Laurence Matthew Skelton reported 0 open-market buys worth $0 and 1 open-market sell worth $66k on SEC Form 4; the latest was sold $66k of VERA on Feb 23, 2026. Grants, option exercises and tax withholding are not counted.
How did Laurence Matthew Skelton's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Laurence Matthew Skelton has 0.
Where does Laurence Matthew Skelton file Form 4?
Laurence Matthew Skelton has filed Form 4 at VERA (Vera Therapeutics, Inc.) as Chief Commercial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.